These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 27333379)
1. Glyco-engineering for the production of recombinant IgA1 with distinct mucin-type O-glycans in plants. Dicker M; Maresch D; Strasser R Bioengineered; 2016 Nov; 7(6):484-489. PubMed ID: 27333379 [TBL] [Abstract][Full Text] [Related]
2. Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy. Novak J; Barratt J; Julian BA; Renfrow MB Semin Nephrol; 2018 Sep; 38(5):461-476. PubMed ID: 30177018 [TBL] [Abstract][Full Text] [Related]
3. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Novak J; Moldoveanu Z; Renfrow MB; Yanagihara T; Suzuki H; Raska M; Hall S; Brown R; Huang WQ; Goepfert A; Kilian M; Poulsen K; Tomana M; Wyatt RJ; Julian BA; Mestecky J Contrib Nephrol; 2007; 157():134-8. PubMed ID: 17495451 [TBL] [Abstract][Full Text] [Related]
4. Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy. Takahashi K; Raska M; Stuchlova Horynova M; Hall SD; Poulsen K; Kilian M; Hiki Y; Yuzawa Y; Moldoveanu Z; Julian BA; Renfrow MB; Novak J PLoS One; 2014; 9(2):e99026. PubMed ID: 24918438 [TBL] [Abstract][Full Text] [Related]
5. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. Tomana M; Novak J; Julian BA; Matousovic K; Konecny K; Mestecky J J Clin Invest; 1999 Jul; 104(1):73-81. PubMed ID: 10393701 [TBL] [Abstract][Full Text] [Related]
6. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study. Gomes MM; Suzuki H; Brooks MT; Tomana M; Moldoveanu Z; Mestecky J; Julian BA; Novak J; Herr AB Biochemistry; 2010 Jul; 49(27):5671-82. PubMed ID: 20507092 [TBL] [Abstract][Full Text] [Related]
7. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system. Novak J; Moldoveanu Z; Julian BA; Raska M; Wyatt RJ; Suzuki Y; Tomino Y; Gharavi AG; Mestecky J; Suzuki H Adv Otorhinolaryngol; 2011; 72():60-3. PubMed ID: 21865691 [TBL] [Abstract][Full Text] [Related]
9. IgA nephropathy and aberrant glycosylation of tonsillar, serum and glomerular IgA1. Hiki Y; Ito A; Yamamoto Y; Yamamoto K; Iwase H Adv Otorhinolaryngol; 2011; 72():68-70. PubMed ID: 21865693 [TBL] [Abstract][Full Text] [Related]
10. O-glycosylation of IgA1 and the pathogenesis of an autoimmune disease IgA nephropathy. Novak J; King RG; Yother J; Renfrow MB; Green TJ Glycobiology; 2024 Sep; 34(11):. PubMed ID: 39095059 [TBL] [Abstract][Full Text] [Related]
11. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Novak J; Julian BA; Tomana M; Mestecky J Semin Nephrol; 2008 Jan; 28(1):78-87. PubMed ID: 18222349 [TBL] [Abstract][Full Text] [Related]
12. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting. Suzuki Y; Suzuki H; Yasutake J; Tomino Y Expert Opin Biol Ther; 2015 Apr; 15(4):583-93. PubMed ID: 25604055 [TBL] [Abstract][Full Text] [Related]
13. N-acetylgalactosaminide α2,6-sialyltransferase II is a candidate enzyme for sialylation of galactose-deficient IgA1, the key autoantigen in IgA nephropathy. Stuchlova Horynova M; Vrablikova A; Stewart TJ; Takahashi K; Czernekova L; Yamada K; Suzuki H; Julian BA; Renfrow MB; Novak J; Raska M Nephrol Dial Transplant; 2015 Feb; 30(2):234-8. PubMed ID: 25281698 [TBL] [Abstract][Full Text] [Related]
14. Cellular signaling and production of galactose-deficient IgA1 in IgA nephropathy, an autoimmune disease. Reily C; Ueda H; Huang ZQ; Mestecky J; Julian BA; Willey CD; Novak J J Immunol Res; 2014; 2014():197548. PubMed ID: 25152896 [TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients. Kosztyu P; Hill M; Jemelkova J; Czernekova L; Kafkova LR; Hruby M; Matousovic K; Vondrak K; Zadrazil J; Sterzl I; Mestecky J; Raska M Kidney Blood Press Res; 2018; 43(2):350-359. PubMed ID: 29529610 [TBL] [Abstract][Full Text] [Related]
16. Cytokines and Production of Aberrantly Person T; King RG; Rizk DV; Novak J; Green TJ; Reily C J Interferon Cytokine Res; 2022 Jul; 42(7):301-315. PubMed ID: 35793525 [TBL] [Abstract][Full Text] [Related]
17. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals. Lehoux S; Mi R; Aryal RP; Wang Y; Schjoldager KT; Clausen H; van Die I; Han Y; Chapman AB; Cummings RD; Ju T Mol Cell Proteomics; 2014 Nov; 13(11):3097-113. PubMed ID: 25071157 [TBL] [Abstract][Full Text] [Related]
19. Separation of Two Distinct O-Glycoforms of Human IgA1 by Serial Lectin Chromatography Followed by Mass Spectrometry O-Glycan Analysis. Lehoux S; Ju T Methods Enzymol; 2017; 585():61-75. PubMed ID: 28109443 [TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases. Stewart TJ; Takahashi K; Xu N; Prakash A; Brown R; Raska M; Renfrow MB; Novak J Glycobiology; 2021 Jun; 31(5):540-556. PubMed ID: 33295603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]